drugset / Trial / NCT07357766

A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight

NCT07357766

Phase 3 Withdrawn Novo Nordisk A/S
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is being done to find out how well a medicine called CagriSema helps people with overweight or obesity lose weight. CagriSema is still being tested in studies and is not yet available for doctors to prescribe. In this study the sponsor will compare two version of CagriSema injected by two different types of injection devices. Which treatment participants get is decided by chance using a computer program, so neither participants nor study staff will know which treatment is given. The study will last for about one year.

Timeline

Start
2026-06-22
Primary completion
2027-11-29
Completion
2028-01-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Cagrilintide Protein / enzyme biologic Subcutaneous
Subject Semaglutide Peptide Subcutaneous

Indications